Description of the medicine: Labetalol (Labetalol)
LABETALOL (Labetalol) *. 5- [1-Oxy-2 - [(1-methyl) -3-phenylpropyl) amino] ethyl] salicylamide, or 2-hydroxy-5- [1-hydroxy] -2 - [(1-methyl-3- phenyl propyl) amino] ethyl] benzamide (hydrochloride).
Synonyms: Abetol, Albetol, Amipress, Ipolab, Labetol, Labrocol, Lamitol, Opercol, Presolol, Trandate, Trandol
It is a b-blocker, which simultaneously has a 1-blocking effect.
The combination of b-adrenergic blocking and peripheral vasodilator action provides a reliable antihypertensive effect. The drug does not significantly affect the amount of cardiac output and heart rate.
Labetalol is used to lower blood pressure with varying degrees of hypertension. Unlike conventional b-blockers, it has a quick antihypertensive effect.
Labetalol is rapidly absorbed when taken orally. The plasma half-life is about 4 hours. It is excreted mainly in the urine in the form of inactive metabolites.
Inside, appoint in the form of tablets (with food) 0.1 g (100 mg) 2 3 times a day. In severe forms of hypertension, the dose is increased. The average daily dose of 600 - 1000 mg in 2 to 4 doses. For maintenance therapy, use 1 tablet (100 mg) 2 times a day.
For hypertensive crises, labetalol is administered intravenously slowly at a dose of 20 mg (2 ml of a 1% solution). If necessary, repeat the injection at intervals of 10 minutes It is preferable to administer labetalol as an infusion. For this, a 1% injection solution in ampoules is diluted with an isotonic solution of sodium chloride or glucose to a concentration of 1 mg / ml. Enter at a rate of 2 ml (2 mg) per minute. Usually the required dose is 50-200 mg.
Intravenous administration is carried out in a hospital with the patient lying down (due to a rapid and significant decrease in blood pressure).
When using labetalol, dizziness (as a phenomenon of postural hypotension), headache, nausea, constipation or diarrhea, a feeling of fatigue, itching,
Labetalol is contraindicated in patients with severe heart failure, atrioventricular block, although in recent years there has been evidence of a favorable effect of intravenous administration of labetalol on systemic, intracardiac and regional hemodynamics in patients with early myocardial infarction.
The drug usually does not cause bronchiolospasm, but caution should be exercised in patients with bronchial asthma.
Method of release: tablets of 0.1 and 0.2 g (100 and 200 mg) of 30 and 100 pieces per pack; 5% solution for injection in ampoules of 5 ml (50 mg per ampoule).
Storage: List B. In the dark place.